Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: HECTOROL

Summary for Tradename: HECTOROL

Suppliers: see list3
patent expirations by year for

Pharmacology for Tradename: HECTOROL

Drug ClassVitamin D2 Analog

Clinical Trials for: HECTOROL

A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis
Status: Completed Condition: Secondary Hyperparathyroidism

Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)
Status: Completed Condition: Chronic Kidney Disease; Secondary Hyperparathyroidism; Chronic Renal Insufficiency; Chronic Renal Failure

A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis
Status: Completed Condition: Moderate to Severe Chronic Plaque Psoriasis

Pilot Study Evaluating Doxercalciferol Replacement Therapy in Kidney Transplant Recipients
Status: Recruiting Condition: Chronic Kidney Disease; Kidney Transplantation

A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease
Status: Completed Condition: Chronic Kidney Disease, Stage 5; Secondary Hyperparathyroidism

Doxercalciferol in Recurrent Pediatric Solid Tumors
Status: Terminated Condition: Solid Tumors

A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection
Status: Completed Condition: Secondary Hyperparathyroidism

A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis
Status: Completed Condition: Secondary Hyperparathyroidism

Comparison of Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease Stage Three and Four
Status: Completed Condition: Secondary Hyperparathyroidism in Chronic Kidney Disease Stage 3 and 4

Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer
Status: Terminated Condition: Prostate Cancer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme Corp
CAPSULE;ORAL020862Apr 23, 2004RXNo5,602,116<disabled><disabled>
Genzyme Corp
CAPSULE;ORAL020862Apr 23, 2004RXNo6,903,083<disabled>YYY<disabled>
Genzyme Corp
CAPSULE;ORAL020862Jul 13, 2009RXNo5,602,116<disabled><disabled>
Genzyme Corp
CAPSULE;ORAL020862Jun 9, 1999RXYes5,602,116<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: HECTOROL

Drugname Dosage Strength RLD Submissiondate
doxercalciferolInjection2 mcg/mL, 1 mL in 2 mL vialHectorol12/28/2011
doxercalciferolCapsules1 mcgHectorol2/12/2010
doxercalciferolCapsules0.5 mcg and 2.5 mcgHectorol3/25/2009
doxercalciferolInjection2 mcg/mL, 2 mL ampulesHectorol10/15/2007

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology